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© 2011 The Japan Society of Histochemistry and The aim of this study was to investigate fascin and podoplanin expression in oral dysplasia
and carcinoma in situ (CIS) immunohistochemically, and to evaluate their relationship to
histopathological diagnosis based on architectural and cytological features. Fascin and
podoplanin expression patterns were analyzed immunohistologically in 26 specimens of
oral lesions, including benign disease (hyperplasia, papilloma, and others), intraepithelial
neoplasia/borderline disease (dysplasia), and malignant disease (CIS, invasive squamous
cell carcinoma). Fascin expression was scored into four original categories, and podoplanin
expression was scored into five previously established categories. The relationship between
the immunohistochemically determined scores of fascin and podoplanin expression and the
architectural and cytological features in the hematoxylin-eosin-stained slides was analyzed
statistically. The immunostaining scores for fascin and podoplanin were significantly higher
in dysplasia and CIS than in benign disease (p=0.0011, p=0.00036), and they were significantly
higher in dysplasia than in benign disease (p=0.0087, p=0.0032). In all cases of invasive
SCC, fascin was expressed mainly in the cytoplasm of the tumor cells and fascin expression
extended from the destruction of the basal layer of the epithelium to the upper layer of the
epithelium and podoplanin was expressed in the cytoplasm and membrane of the tumor
cells. This was the first report of up-regulation of fascin in oral dysplasia. Our results suggest
that it would be helpful for improving the diagnostic accuracy of oral dysplasia and CIS to
assess the expression of fascin and podoplanin immunohistochemically.
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I. Introduction
In the WHO classification, epithelial precursor and
related lesions are histopathologically classified into squa-
mous cell hyperplasia and mild, moderate, and severe
dysplasia and carcinoma in situ (CIS) by the assessment of
the presence and severity of epithelial dysplasia based on
architectural and cytological features [5]. Oral dysplasia
typically progresses through a sequence of histopathological
lesions, including mild, moderate to severe dysplasia,
CIS, and finally invasive cancer. Oral leukoplakia (OL) is
‘a white patch’ diagnosed by clinical finding and gross
pathology, that includes hyperplasia, dysplasia, CIS, inva-
sive squamous cell carcinoma (SCC), and other diseases
histopathologically. The progress rates into invasive SCC
of OL diagnosed with hyperplasia or dysplasia histopatho-
logically have been reported to range from 17% in a series
of patients followed-up for 8 years [29] to 31% in a series
followed-up for 7 years [17]. Because the 5-year survival
rate of oral squamous cell carcinoma (OSCC) is aroundShimamura et al. 240
50%, and the tumor-node-metastasis (TNM) stage at
presentation significantly affects 5-year survival, early
diagnosis and treatment are crucial for reducing mortality
from this disease [31]. Therefore, we consider that appro-
priate diagnosis and management of epithelial precursor
lesions may allow us to manage appropriately the intra-
epithelial neoplasia/borderline disease or to provide early
treatment of cancer and thereby help to decrease the number
of deaths from OSCC.
However, it has been reported that histopathological
assessment of the presence and severity of epithelial
dysplasia based on architectural and cytological features is
inconsistent, with substantial levels of inter- and intra-
observer variation [1, 13]. Further, it is often difficult to
distinguish between dysplasia and other benign lesions,
because oral benign lesions other than dysplasia also
frequently show architectural disturbance and cytological
atypia. Therefore, in addition to assessing epithelial dys-
plasia morphologically, objective biomarkers that do not
require the ability to recognize morphologic changes
would be helpful for a more precise histopathological
diagnosis of dysplasia. In this context, we have become
interested in fascin and podoplanin as potentially key
factors for the diagnosis of dysplasia.
Fascin, which is an actin-bundling protein, plays a role
in cell transformation and in increasing cell motility [2].
The expression of fascin protein is often up-regulated in
several types of human neoplasm, including oral [4, 18],
breast [7, 35], pancreatic [19], colonic [12], and lung tumors
[24], and the overexpression of fascin has been implicated
in tumor progression [11]. However, there have been no
studies on fascin expression in oral dysplasia.
Podoplanin, which belongs to the family of type-1
transmembrane sialomucin-like glycoproteins, is specifi-
cally expressed in the lymphatic vascular endothelium [3,
23, 25]. It is also expressed in tumor cells of various types
of cancer, such as SCC in several organs [16, 26, 27, 36],
germ cell tumors [27], vascular tumors [8], malignant
mesothelioma [15], and tumors of the central nervous system
[21], and has been shown to play a role in tumor invasion
and metastasis through its ability to remodel actin in the
cytoskeleton of tumor cells [32]. In addition, it was reported
that podoplanin was overexpressed in oral dysplasia and
lichen planus, which the World Health Organization (WHO)
classifies as being potentially malignant disorders [14, 28].
And recently, the role of podoplanin in early oral tumori-
genesis has also begun to attract attention.
The aim of this study was to search for objective
Table 1. Patient’s histopathological data
M/F, male/female; SCC, squamous cell carcinoma; ‡ are impossible to score.
Case No. Age, years Sex location Histopathology by HE
Immunohistochemical score
Fascin Podoplanin
1 71 M Tongue Hyperplasia 0 0
2 84 M Tongue Hyperplasia 0 0
3 36 M Tongue Fibroepithelial polyp 1 0
4 53 M Tongue Fibroepithelial polyp 1 0
5 64 M Tongue Fibroma 0 0
6 74 F Tongue Fibroma 1 0
7 71 M Tongue Papilloma 1 1
8 53 F Tongue Papilloma 2 0
9 64 M Tongue Papilloma 3 1
10 37 F Tongue Mild dysplasia 3 1
11 67 M Lower alveolus Mild dysplasia 3 3
12 72 M Tongue Mild dysplasia 3 4
13 37 M Tongue Moderate dysplasia 3 1
14 44 M Tongue Severe dysplasia 2 4
15 44 F Tongue Severe dysplasia 3 4
16 74 M Tongue Severe dysplasia 3 4
17 66 M Tongue Carcinoma in situ 34
18 72 F Tongue Carcinoma in situ 34
19 62 F Tongue Carcinoma in situ 34
20 63 F Tongue Carcinoma in situ 34
21 58 F Hard palate Invasive SCC ‡ ‡
22 68 F Upper alveolus Invasive SCC ‡ ‡
23 38 M Tongue Invasive SCC ‡ ‡
24 64 M Tongue Invasive SCC ‡ ‡
25 66 M Tongue Invasive SCC ‡ ‡
26 81 M Tongue Invasive SCC ‡ ‡A Possible Utility of Fascin and Podoplanin for Oral Dysplasia 241
biomarkers to improve the diagnostic accuracy for epithelial
dysplasia. To this end, we examined the expression pat-
terns of fascin and podoplanin immunohistochemically in
dysplasia and CIS of oral lesions, and evaluated their
relationship to the histopathological diagnosis based on
architectural and cytological features.
II. Materials and Methods
Patients and tissue specimens
Tissue specimens of 26 patients were collected from
Saitama Medical University Hospital and Saitama Medical
University International Medical Center from April 2005 to
August 2010 (Table 1). Surgically removed specimens or
biopsy specimens were included in the current study. Patients
were diagnosed with dysplasia and CIS histopathologically
by the 2005 WHO classification. Patients with benign
disease (2 cases of hyperplasia, 2 cases of fibroma, 2 cases
of fibroepithelial polyp, 3 cases of papilloma) or malignant
carcinoma (6 cases of invasive SCC) were selected as
comparison subjects.
The average age of the patients was 60.9 (range 36–
84) years. Seventeen of the patients were male and nine
were female. Tissue specimens included 23 tongue lesions,
2 gingival lesions, and 1 palate lesion. This study was
approved by an ethics review board and informed consent
was obtained from patients.
Tissue processing
Tissue sections (4 µm thick) from formalin-fixed,
paraffin-embedded tissue blocks of surgical specimens or
biopsy specimens were mounted on positively charged glass
slides.
Immunohistochemical procedure
Immunohistochemistry was performed using the
avidin-biotin peroxidase complex technique. In brief,
slides were deparaffinized through a series of xylene baths
and rehydrated with graded concentrations of alcohol. The
slides were then steamed with 10 mmol/L citrate buffer
(pH 6.0; DAKO Cytomation, Carpinteria, CA) for 20 min,
immersed in methanol containing 3% hydrogen peroxide for
10 min, and incubated in 10% horse serum for 30 min at
room temperature. The slides were incubated with specific
primary antibodies raised against fascin (mouse monoclonal
antibody, clone 55K-2; DAKO) at a 1:100 dilution and
podoplanin (mouse monoclonal antibody, clone NZ-1;
AngioBio, Del Mar, CA) at a 1:200 dilution at 37°C for 32
min. Immunostaining with an iVIEW DAB Detection Kit
(Ventana Medical Systems Inc., AZ) and BenchMark XT
(Ventana Medical Systems) was performed. Adjacent
normal-appearing endothelial cells of blood vessels were
used as positive controls for fascin [6], and adjacent
normal-appearing lymphatic endothelial cells within the sec-
tions served as positive controls for podoplanin [3, 23, 25].
Immunohistochemical evaluation
Cells showing any cytoplasmic immunoreactivity were
considered positive for fascin expression. To score the fascin
expression, we used a newly developed system with four
original categories based on the level of epithelial staining
(Fig. 1, upper panel). The expression was scored as 0 if no
expression was observed in any part of the epithelium; 1 if
expression was restricted to one-third of the epithelium
beginning in the basal layer; 2 if expression was observed
in two-thirds of the epithelium beginning in the basal layer;
and 3 if expression was observed in all areas of the
Fig. 1. Schema of the expression patterns with scores. The patterns of expression scores for fascin and podoplanin. The upper panel shows
representative expression profiles of fascin corresponding to scores 0 to 3. Score 0: no expression observed in any part of the epithelium. Score
1: expression restricted to one-third of the epithelium beginning in the basal layer. Score 2: expression observed in two-thirds of the epithelium
beginning in the basal layer. Score 3: expression observed in all areas of the epithelium. The lower panel shows representative expression
profiles of podoplanin corresponding to scores 0 to 4. Score 0: no expression observed in any part of the epithelium. Score 1: expression
restricted to the basal layer of the epithelium. Score 2: expression observed in the basal and suprabasal layers in one area. Score 3: suprabasal
layer expression is observed in two or three areas. Score 4: suprabasal layer expression is observed in more than three areas.Shimamura et al. 242
epithelium.
Cells showing any membrane immunoreactivity were
considered positive for podoplanin expression. Podoplanin
expression was scored into five categories based on the
staining level of the epithelium, as reported by Kawaguchi
et al. (Fig. 1, lower panel) [6]. The expression was scored
as 0 if no expression was observed in any parts of the
epithelium; 1 if expression was restricted to the basal layer
of the epithelium; 2 if expression was observed in the basal
and suprabasal layers in one area in a slice preparation; 3
if suprabasal layer expression was observed in two or three
areas in a slice preparation; and 4 if suprabasal layer
expression was observed in more than three areas in a slice
preparation.
The whole sections were stained with the classic
hematoxylin-eosin (HE) staining technique and diagnosed
histopathologically by experienced pathologists. When
examining the histopathology of the sections, classifications
CIS, OSCC, or mild, moderate, or severe dysplasia were
histopathologically graded according to the latest WHO
guidelines [5].
Statistical analysis
The relationship between the immunohistochemically
determined scores of fascin and podoplanin expression and
the architectural and cytological features in HE-stained
slides was analyzed using the Wilcoxon rank sum test. P
values <0.05 were considered to be statistically significant.
III. Results
Correlation between fascin expression and architectural 
and cytological features
Fascin expression in interstitial tissue was consistently
detected in endothelial cells of the vessels (arrows in Fig. 2F,
HE staining: Fig. 2A). Fascin expression in the normal
squamous epithelium was extremely low in basal cells (not
shown). Because fascin was mainly expressed in the
cytoplasm in oral lesions (Fig. 2K–M), we observed wide
fascin expression throughout the basal layer of the epithe-
lium (Fig. 2G–I, HE staining: Fig. 2B–D). In Figure 2G, the
fascin expression is partially restricted to under one-third
of the epithelium beginning in the basal layer. In Figure 2I,
we show fascin expression in all areas of the epithelium.
Among the samples from subjects with benign disease
(hyperplasia, fibroepithelial polyp, fibroma, or papilloma),
3 out of 9 had no detectable fascin expression, and 4 out
of 9 showed fascin expression only in one-third of the
epithelium beginning in the basal layer (scored as 1)
(Table 1). Fascin expression in two-thirds of the epithelium
beginning in the basal layer (scored as 2) and fascin
expression in all areas of the epithelium (scored as 3) were
each seen in 1 out of the 9 cases.
In the cases with dysplasia, the fascin-expression scores
were a relatively high 2 or 3: 1 out of the 7 cases showed
fascin expression in two-thirds of the epithelium beginning
in the basal layer (scored as 2), and 6 out of 7 showed fascin
expression in all areas of the epithelium (scored as 3). In
all cases (4/4) of CIS, fascin was expressed in all area of
the epithelium (scored as 3).
The immunostaining scores for fascin were signifi-
cantly higher in dysplasia and CIS than in the benign diseases
(hyperplasia, fibroepithelial polyp, fibroma, or papilloma)
(p=0.0011). Further, the immunostaining scores for fascin
were significantly higher in dysplasia than in the cases of
benign disease (hyperplasia, fibroepithelial polyp, fibroma,
or papilloma) (p=0.0087). The immunostaining scores for
fascin were not statistically different between dysplasia and
CIS (p=0.45).
Correlation between the podoplanin expression and 
architectural and cytological features
As expected, podoplanin was highly expressed in the
endothelial cells of lymphatic vessels (arrows in Fig. 3G,
HE staining: Fig. 3A), but was not detectable in the
endothelial cells of blood vessels. Podoplanin expression
Fig. 2. Expression patterns of fascin. A–E: Hematoxylin and eosin staining. F–L: Expression patterns of fascin. The blue arrows indicate blood
vessels. The square indicates magnified images. Magnification ×100 (A–J), ×400 (K–M). A, F: score 0, hyperplasia; B, G, K: score 1, mild
dysplasia; C, H, L: score 2, severe dysplasia; D, I, M: score 3, carcinoma in situ; E, J: invasive SCC.A Possible Utility of Fascin and Podoplanin for Oral Dysplasia 243
was not detectable in the normal squamous epithelium (not
shown). In oral lesions, podoplanin expression was highly
variable in the epithelium (Fig. 3H–K, HE staining: Fig. 3B–
E). Podoplanin was expressed mainly in the membrane
region of the basal layer (Fig. 3M–O). In some cases,
podoplanin was highly expressed on the cell membrane
predominantly at the basal layer (Fig. 3H); in other cases
the expression extended to the suprabasal layer (Fig. 3I–K).
In the benign diseases (hyperplasia, fibroepithelial
polyp, fibroma, papilloma), podoplanin expression was low,
with scores of 0 or 1: 7 of 9 cases showed no detectable
podoplanin expression in the epithelium (scored as 0), and
2 out of 9 showed podoplanin expression only in certain
basal layer cells (scored as 1) (Table 1).
In dysplasia, podoplanin expression was variable in the
epithelium: 2 out of 7 cases showed podoplanin expression
only in certain basal layer cells (scored as 1), 1 out of 7
showed podoplanin expression in the suprabasal layer in
two or three areas (scored as 3), and 4 out of 7 showed
podoplanin expression in the suprabasal layer in more than
three areas (scored as 4). In all cases (4/4) of CIS, podoplanin
expression was given the highest score of 4: present in the
suprabasal layer in more than three areas.
The immunostaining scores for podoplanin were sig-
nificantly higher in dysplasia and CIS than in the benign
disease (hyperplasia, fibroepithelial polyp, fibroma, or
papilloma) (p=0.00036). Further, the immunostaining scores
for podoplanin were significantly higher in dysplasia than
in the benign disease (hyperplasia, fibroepithelial polyp,
fibroma, or papilloma) (p=0.0032). The immunostaining
scores for podoplanin were not statistically different between
dysplasia and CIS (p=0.15).
Fascin and podoplanin expression in invasive OSCC
Because the tumor cells invaded into the lamina propria,
destroying the basal layer of the epithelium, we were unable
to score the fascin and podoplanin expression in invasive
SCC (Table 1). But in all cases (6/6) of invasive SCC, fascin
was expressed mainly in the cytoplasm of the tumor cells
and fascin expression extended from the destruction of the
basal layer of the epithelium to the upper layer of the
epithelium (Fig. 2J, HE staining: Fig. 2E). Further, in all
cases (6/6) of invasive SCC, podoplanin was expressed in
the cytoplasm and membrane of the tumor cells (Fig. 3L,
HE staining: Fig. 3F).
IV. Discussion
Fascin has a major function in forming the parallel
actin bundles that support lamellipodial and filopodial cell
protrusions, which are the key cellular structures for
environmental guidance and cell migration, and play roles
in cell transformation and cell motility [2]. Fascin is normally
expressed in vascular endothelial cells and fibroblasts [6],
and it has been reported that fascin is usually present at low
levels in stratified basaloid squamous cells of the esophagus
[9]. Previous data from a number of laboratories have
highlighted that fascin is up-regulated in many human
carcinomas and, in individual tissues, it correlates with the
clinical aggressiveness of the tumor and with poor patient
survival [4, 7, 11, 12, 18, 19, 24, 35]. These findings indicate
that fascin may functionally contribute to disease progression
[11].
Chen et al. reported that expression of fascin was up-
regulated in most of their series of OSCC, though variability
and heterogeneity in the intensity and distribution of fascin
expression were present [4]. In other reports, intense staining
of fascin protein was identified at the invasive fronts or
infiltrating borders of most cases of OSCC, and over-
expression of fascin was found to contribute to a more
aggressive OSCC [4, 18]. In agreement with the previous
reports, all of the present cases with invasive OSCC showed
overexpression of fascin mainly in the cytoplasm of the
tumor cells invading into the lamina propria. Fascin
expression extended from the invasive fronts to the upper
layer of the epithelium.
Previous reports on fascin have mostly focused on the
fascin expression in human carcinomas [4, 7, 11, 12, 18, 19,
24, 35]. But in the current study, we focused on when
the up-regulation of fascin occurred during the process of
Fig. 3. Expression patterns of podoplanin. A–F: Hematoxylin and eosin staining. G–O: Expression patterns of podoplanin. The arrows indicate
lymphatic endothelial cells. The square indicates magnified images with positive podoplanin expression. Magnification ×100 (A–C, F, G–I, L),
×40 (D, E, J, K), ×400 (M–O). A, G: score 0, hyperplasia; B, H: score 1, mild dysplasia; C, I, M: score 2, mild dysplasia; D, J, N: score 3, mild
dysplasia; E, K, O: score 4, carcinoma in situ; F, L: invasive SCC.Shimamura et al. 244
malignant transformation and development of neoplasm. In
previous studies, fascin overexpression has been observed
in precancerous lesions or CIS, dysplasia of the esophagus
[37], sinonasal inverted papilloma with dysplasia [30],
adenoma of the colorectum [10], and intraductal papillary
mucinous adenoma or borderline neoplasm of the pancreas
[34]. Further, Yamaguchi et al. showed that fascin over-
expression  in  intraductal  papillary  mucinous  neoplasms
of the pancreas were correlated with increased histological
grade by immunohistochemical analysis [34]. Fascin may
therefore contribute to the early stage of carcinogenesis. In
this study, up-regulation of fascin was observed in oral
dysplasia and CIS. To our knowledge, this is the first re-
port that showed up-regulation of fascin appearing at an
early stage of malignant transformation in oral lesions. Our
research showed that fascin expression was not detectable
in hyperplasia and the immunostaining scores for fascin
were significantly higher in dysplasia and CIS than in
benign disease. In all cases of invasive OSCC, overexpres-
sion of fascin extended from the destruction of the basal
layer of the epithelium to the upper layer of the epithelium.
This finding supported the reports of Zhang et al. that the
level of fascin expression and frequency of overexpression
increased gradually in the progression from normal epithe-
lium to simple hyperplasia, dysplasia, CIS, and finally
invasive esophageal squamous cell carcinoma [37].
It is reported that approximately 90% of OSCCs ex-
press podoplanin, which is restricted to the invasive front
of the tumor, and high expression levels are associated with
lymph node metastasis and a poor clinical outcome [16, 36].
In agreement with previous reports, our research showed
podoplanin was overexpressed in the cytoplasm and mem-
brane of the tumor cells invading into the lamina propria in
all cases of invasive OSCC. Several studies showed that
podoplanin remodeled the actin cytoskeleton of tumor cells,
contributing to their increased migration and invasion [20,
22, 33]. The association of podoplanin with the actin-
cytoskeleton was mediated by an ERM protein called ezrin.
Ezrin was markedly phosphorylated and it induced re-
modeling of the actin cytoskeleton, thereby contributing to
migration and invasion of cancer cells, when podoplanin
was over-expressed. In addition, it has been reported that
podoplanin modulates the activities of Rho GTPases, mainly
RhoA, by inducing reorganization of the actin cytoskeleton
[20, 33].
In intraepithelial neoplasia/borderline diseases, reports
have revealed that podoplanin is highly expressed in the
basal cell layers in some of the hyperplastic and dysplastic
areas adjacent to the SCC [36]. Kawaguchi et al. showed
that 37% of OL lesions diagnosed with hyperplasia or dys-
plasia histopathologically, exhibited podoplanin expression
patterns similar to those found in OSCC immunohisto-
chemically. They suggested that patients with podoplanin
expressed lesions had a significantly higher incidence of
invasive oral cancer, therefore podoplanin was a promising
biomarker for predicting the risk of oral cancer develop-
ment [14]. Moreover, it was reported that podoplanin was
abnormally expressed in lichen planus, which the WHO
classifies as being a potentially malignant disorder, with the
malignant transformation risk being much greater in patients
with podoplanin over-expression [28]. These data highlight
the importance of podoplanin detection in early oral tumor-
igenesis, suggesting that podoplanin may be used as a
biomarker for risk assessment of malignant transformation
in patients with potentially malignant oral disorders.
In the WHO criteria [5], the term dysplasia applies
when architectural disturbance is histopathologically accom-
panied by cytological atypia (variations in the size and shape
of the keratinocytes). However, oral benign lesions other
than dysplasia also frequently show architectural disturb-
ances and cytological atypia, which include reactive atypia
known as inflammatory atypia and regenerative atypia,
therefore it is often difficult to distinguish between dysplasia
and other benign lesions. In our study, the immunostaining
scores for fascin and podoplanin were significantly higher
in dysplasia and CIS than in benign disease, and they were
significantly higher in dysplasia than in benign disease.
These findings suggest that oral dysplasia and CIS could be
distinguished from other oral lesions by assessing the
expression of fascin and podoplanin immunohistochemi-
cally, and that such assessment could improve the diagnostic
accuracy of oral dysplasia and CIS.
In summary, this is the first report of an up-regulation
of fascin occurring early in the progression from normal
epithelium to invasive OSCC. Our results demonstrated that
it was helpful for improving the diagnostic accuracy of oral
dysplasia and CIS to assess the expression of fascin and
podoplanin immunohistochemically.
A summary of this work was presented at the 33rd
Annual Meeting of the Japan Society for Head and Neck
Cancer (June 11, 2009, Tokyo).
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